EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Remo Panaccione  ¹     Anita Afzali  ²     David P. Hudesman  ³     Garrett Lawlor  ⁴     Mark T. Osterman  ⁴     Arteid Memaj  ⁴     Miguel Regueiro  ⁵     Subrata Ghosh  ^6    
1 Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
² The Ohio State University Wexner Medical Center, Columbus, United States
³ NYU Langone Health, New York, United States
⁴ Bristol Myers Squibb, Princeton, United States
⁵ Cleveland Clinic, Cleveland, United States
⁶ College of Medicine and Health, University College Cork, Cork, Ireland

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in ulcerative colitis II

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)